New Zealand markets closed

Amplia Therapeutics Limited (ATX.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0640+0.0030 (+4.92%)
At close: 04:10PM AEST
Full screen
Previous close0.0610
Open0.0610
Bid0.0580 x 3463500
Ask0.0660 x 4114300
Day's range0.0610 - 0.0660
52-week range0.0550 - 0.0940
Volume462,717
Avg. volume225,967
Market cap17.383M
Beta (5Y monthly)0.53
PE ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings date30 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Allan Moss Buys 40% More Amplia Therapeutics Shares

    Investors who take an interest in Amplia Therapeutics Limited ( ASX:ATX ) should definitely note that insider Allan...

  • PR Newswire

    FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

    Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.